![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 8 of 8. This is the beginning of the thread.
Posted by zeugma on October 19, 2004, at 18:28:46
this study suggests a possible rationale for augmentation strategy if Cymbalta fails to do the trick alone...
Brain Res. 2002 Dec 20;958(1):161-5. Related Articles, Links
Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.Yamada J, Sugimoto Y.
Department of Pharmacology, Kobe Pharmaceutical University, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan. j-yamada@kobepharma-u.ac.jp
The effects of the 5-HT(2) receptor antagonist, LY 53857 on the effects of noradrenaline and serotonin reuptake inhibitors were investigated using the forced swimming test. LY 53857 enhanced anti-immobility effects of clomipramine and maprotiline, which can inhibit reuptake of noradrenaline. However, LY 53857 did not affect the immobility time of mice treated with the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine. These results suggest that antagonism of the 5-HT(2) receptor leads to potentiation of the antidepressant effects of noradrenaline reuptake inhibitors but not SSRIs and that LY 53857 may modify the activity of noradrenergic neurons. Copyright 2002 Elsevier Science B.V.
PMID: 12468041 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------------------------
Posted by King Vultan on October 19, 2004, at 19:25:53
In reply to synergism of 5HT2 antagonism + NRI, posted by zeugma on October 19, 2004, at 18:28:46
Well, clomipramine is also an SSRI, even though it is a TCA. Based on what I know of 5-HT2 antagonism, I really have to question if they haven't jumped to an erroneous conclusion.
Todd
Posted by zeugma on October 19, 2004, at 19:44:51
In reply to Re: synergism of 5HT2 antagonism + NRI, posted by King Vultan on October 19, 2004, at 19:25:53
i suppose it depends on whether the study was done at a time when sufficient exposure to clomipramine had occurred to permit formation of its desmethyl metabolite, which does inhibit reuptake of NE.
Posted by jboud24 on October 19, 2004, at 22:42:06
In reply to Re: synergism of 5HT2 antagonism + NRI, posted by zeugma on October 19, 2004, at 19:44:51
That's an interesting article, although I'm left wondering about what the implications are. Perhaps a direct displacement of 5-HT leading to more available 5-HT in the synapse? Perhaps this is giving a kick to the NRI's by adding a second serotonin mediated anti-depressant response. I dunno. I wouldn't read too much into though since humans aren't rats, and the forced swim test is jst one measure of anti-depressant activity.
Justin
Posted by Sad Panda on October 21, 2004, at 9:35:32
In reply to synergism of 5HT2 antagonism + NRI, posted by zeugma on October 19, 2004, at 18:28:46
> this study suggests a possible rationale for augmentation strategy if Cymbalta fails to do the trick alone...
>
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12468041
>
> Brain Res. 2002 Dec 20;958(1):161-5. Related Articles, Links
>
>
> Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
>
> Yamada J, Sugimoto Y.
>
> Department of Pharmacology, Kobe Pharmaceutical University, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan. j-yamada@kobepharma-u.ac.jp
>
> The effects of the 5-HT(2) receptor antagonist, LY 53857 on the effects of noradrenaline and serotonin reuptake inhibitors were investigated using the forced swimming test. LY 53857 enhanced anti-immobility effects of clomipramine and maprotiline, which can inhibit reuptake of noradrenaline. However, LY 53857 did not affect the immobility time of mice treated with the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine. These results suggest that antagonism of the 5-HT(2) receptor leads to potentiation of the antidepressant effects of noradrenaline reuptake inhibitors but not SSRIs and that LY 53857 may modify the activity of noradrenergic neurons. Copyright 2002 Elsevier Science B.V.
>
> PMID: 12468041 [PubMed - indexed for MEDLINE]
>
> --------------------------------------------------------------------------------
>Looks like Nortriptyline is just what you need! Lilly would still be selling the stuff except that they can't make huge profits from it.
Cheers,
Paul.
Posted by zeugma on October 21, 2004, at 16:34:27
In reply to Re: synergism of 5HT2 antagonism + NRI, posted by Sad Panda on October 21, 2004, at 9:35:32
yes, that is not why i am going off it anytime soon.
-z
Posted by Iansf on October 22, 2004, at 19:26:38
In reply to Re: synergism of 5HT2 antagonism + NRI, posted by Sad Panda on October 21, 2004, at 9:35:32
> > this study suggests a possible rationale for augmentation strategy if Cymbalta fails to do the trick alone...
> >
> >
For those of us with less background in science, what is the possible augmentation strategy? Thanks.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12468041
> >
> > Brain Res. 2002 Dec 20;958(1):161-5. Related Articles, Links
> >
> >
> > Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
> >
> > Yamada J, Sugimoto Y.
> >
> > Department of Pharmacology, Kobe Pharmaceutical University, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan. j-yamada@kobepharma-u.ac.jp
> >
> > The effects of the 5-HT(2) receptor antagonist, LY 53857 on the effects of noradrenaline and serotonin reuptake inhibitors were investigated using the forced swimming test. LY 53857 enhanced anti-immobility effects of clomipramine and maprotiline, which can inhibit reuptake of noradrenaline. However, LY 53857 did not affect the immobility time of mice treated with the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine. These results suggest that antagonism of the 5-HT(2) receptor leads to potentiation of the antidepressant effects of noradrenaline reuptake inhibitors but not SSRIs and that LY 53857 may modify the activity of noradrenergic neurons. Copyright 2002 Elsevier Science B.V.
> >
> > PMID: 12468041 [PubMed - indexed for MEDLINE]
> >
> > --------------------------------------------------------------------------------
> >
>
> Looks like Nortriptyline is just what you need! Lilly would still be selling the stuff except that they can't make huge profits from it.
>
> Cheers,
> Paul.
>
Posted by DynaUnity333 on October 23, 2004, at 6:07:36
In reply to Re: synergism of 5HT2 antagonism + NRI, posted by Sad Panda on October 21, 2004, at 9:35:32
> > this study suggests a possible rationale for augmentation strategy if Cymbalta fails to do the trick alone...
> >
> > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12468041
> >
> > Brain Res. 2002 Dec 20;958(1):161-5. Related Articles, Links
> >
> >
> > Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
> >
> > Yamada J, Sugimoto Y.
> >
> > Department of Pharmacology, Kobe Pharmaceutical University, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan. j-yamada@kobepharma-u.ac.jp
> >
> > The effects of the 5-HT(2) receptor antagonist, LY 53857 on the effects of noradrenaline and serotonin reuptake inhibitors were investigated using the forced swimming test. LY 53857 enhanced anti-immobility effects of clomipramine and maprotiline, which can inhibit reuptake of noradrenaline. However, LY 53857 did not affect the immobility time of mice treated with the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine. These results suggest that antagonism of the 5-HT(2) receptor leads to potentiation of the antidepressant effects of noradrenaline reuptake inhibitors but not SSRIs and that LY 53857 may modify the activity of noradrenergic neurons. Copyright 2002 Elsevier Science B.V.
> >
> > PMID: 12468041 [PubMed - indexed for MEDLINE]
> >
> > --------------------------------------------------------------------------------
> >
>
> Looks like Nortriptyline is just what you need! Lilly would still be selling the stuff except that they can't make huge profits from it.
>
> Cheers,
> Paul.
>
Thats exactly what i was going to say panda.The title of this thread sounds just like Nort to me.
Whats the point in trying to find two meds to do the same thing that one tried and trusted one can do all by itself.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.